PepGen to Participate in the SVB Securities Global Biopharma Conference
February 09, 2023 08:00 ET
|
PepGen Inc.
BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming...
PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies
December 07, 2022 08:00 ET
|
PepGen Inc.
- PGN-EDODM1 was well-tolerated in acute GLP studies in rodents and non-human primates (NHPs) at clinically relevant doses- - Studies conducted in patient cells indicate that PGN-EDODM1, a...
PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates
November 14, 2022 08:00 ET
|
PepGen, Inc
- In non-human primates (NHPs), high levels of exon 53 skipping were observed after a single dose of PGN-EDO53 – almost 7-times higher than those observed for a comparator peptide-phosphorodiamidate...
PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
November 10, 2022 08:00 ET
|
PepGen, Inc
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming...
PepGen to Participate in the Stifel 2022 Healthcare Conference
November 08, 2022 08:00 ET
|
PepGen, Inc
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming...
PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress
October 13, 2022 13:00 ET
|
PepGen, Inc
BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming...
PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
September 28, 2022 06:00 ET
|
PepGen, Inc
- PGN-EDO51 exhibited the highest levels of oligonucleotide delivery and exon skipping in a clinical study following a single dose when compared to publicly available clinical data for other exon 51...
PepGen Appoints Habib Dable to Board of Directors
September 22, 2022 08:00 ET
|
PepGen, Inc
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the...
PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
August 12, 2022 08:00 ET
|
PepGen, Inc
BOSTON, Aug. 12, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the...
PepGen Appoints Caroline Godfrey, Ph.D. to the Company’s Scientific Advisory Board
July 22, 2022 07:45 ET
|
PepGen, Inc
BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a Boston-based clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...